A new study—published this week in Science Advances—uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma.
A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow.
